Chemical Biology Unit, Institute of Nano Science and Technology, Sector-81, Knowledge City, Sahibzada Ajit Singh Nagar, Mohali, Punjab 140306, India.
National Agri-Food Biotechnology Institute, Mohali, Punjab 140306, India.
ACS Biomater Sci Eng. 2023 Aug 14;9(8):4781-4793. doi: 10.1021/acsbiomaterials.3c00480. Epub 2023 Jul 27.
Ulcerative colitis (UC) is a chronic inflammation-related disease that severely affects the colon and rectum regions. A variety of therapy regimens are used for the treatment of UC. Clinically, therapeutic enema is the choice of therapy for UC patients. Irrespective of on-site administration, the major limitation of therapeutic enemas is the dispossession of the medicine followed by low drug availability for the therapeutic action. In our present work, we have developed an enzyme-responsive injectable hydrogel (ER-hydrogel) to overcome the limitations of therapeutic enema. The hydrogels possess two major advantages, which are being exploited for therapeutic drug delivery in UC: prolonged retention and enzyme responsiveness. The former is one of the prominent advantages of hydrogel compared to free drug enema and the latter controls the release of the drug or provides drug release on-demand. The ER-hydrogel was formulated by the heat-cool method and for therapeutic purposes, a corticosteroid drug, budesonide (Bud), was encapsulated into the ER-hydrogel and evaluated for its various physicochemical and therapeutic potentials in dextran sodium sulfate (DSS)-induced UC. In vitro and ex vivo adhesion studies confirm the retention or mucoadhesive nature of the ER-hydrogel, and the upsurge in Bud release from the Bud-loaded ER-hydrogel upon the addition of esterase enzyme confirms the enzyme-mediated drug release from the ER-hydrogel. Moreover, Bud-loaded ER-hydrogel exhibited promising results in alleviating the disease activity index of UC, and restored the length of the colon, which is the main hallmark of UC. In terms of the health of the colon tissue, the Bud-loaded ER-hydrogel restored the colonic tissue damage, as seen in the H&E-stained, AB-NR-stained, and HID-AB-stained colon sections. Finally, the Bud-loaded ER-hydrogel also markedly subsided the IL-1β, TNF-α, MPO, and nitrite levels in serum and colon tissues. Thus, the fabricated Bud-loaded ER-hydrogel possesses appreciable translational potential due to its ability to significantly ameliorate inflammatory changes compared to naive or water-based therapeutic enema in acute experimental colitis in mice.
溃疡性结肠炎(UC)是一种严重影响结肠和直肠区域的慢性炎症相关疾病。有多种治疗方案用于治疗 UC。临床上,治疗性灌肠是 UC 患者的治疗选择。无论在现场给药,治疗性灌肠的主要限制是药物的丧失,随后是用于治疗作用的药物可用性低。在我们目前的工作中,我们开发了一种酶响应型可注射水凝胶(ER-水凝胶),以克服治疗性灌肠的局限性。水凝胶具有两个主要优势,这两个优势被用于 UC 的治疗药物输送:延长保留时间和酶响应性。前者是水凝胶与游离药物灌肠相比的突出优势之一,后者控制药物的释放或按需提供药物释放。ER-水凝胶通过热-冷法进行配方,并且为了治疗目的,将皮质类固醇药物布地奈德(Bud)包封到 ER-水凝胶中,并评估其在葡聚糖硫酸钠(DSS)诱导的 UC 中的各种物理化学和治疗潜力。体外和离体粘附研究证实了 ER-水凝胶的保留或粘膜粘附性质,并且在加入酯酶后,Bud 从负载 Bud 的 ER-水凝胶中的释放增加,证实了 ER-水凝胶中药物的酶介导释放。此外,负载 Bud 的 ER-水凝胶在减轻 UC 的疾病活动指数方面表现出有希望的结果,并恢复了结肠的长度,这是 UC 的主要标志。就结肠组织的健康而言,负载 Bud 的 ER-水凝胶恢复了结肠组织损伤,如 H&E 染色、AB-NR 染色和 HID-AB 染色的结肠切片所示。最后,负载 Bud 的 ER-水凝胶还显著降低了血清和结肠组织中 IL-1β、TNF-α、MPO 和亚硝酸盐水平。因此,与基于水的治疗性灌肠相比,负载 Bud 的 ER-水凝胶由于其能够显著改善炎症变化,因此具有可观的转化潜力,在急性实验性结肠炎小鼠中。